Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of atezolizumab with or without tiragolumab after definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma
CTR20201983Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, tiragolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Roche. Started Mar 2021; status: active.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201983.